Name | sr 2211 |
---|---|
Synonyms |
1,1,1,3,3,3-Hexafluoro-2-(2-fluoro-4'-{[4-(4-pyridinylmethyl)-1-piperazinyl]methyl}-4-biphenylyl)-2-propanol
[1,1'-Biphenyl]-4-methanol, 2-fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-α,α-bis(trifluoromethyl)- |
Description | SR2211 is a potent, selective synthetic RORγ modulator and functions as an inverse agonist, with a Ki of 105 nM and an IC50 of ~320 nM. |
---|---|
Related Catalog | |
Target |
IC50: ~320 nM (RORγ), Ki: 105 nM (RORγ)[1][2]. |
In Vitro | The treatment of EL4 with SR2211 represses the Il17 gene expression to a greater extent as compared to digoxin. Similarly, the expression of IL-23 receptor (Il23r) is significantly inhibited by SR2211 and digoxin, as has been previously reported. Treatment of EL-4 cells with SR2211 as well as a control digoxin results in significant inhibition of IL-17 intracellular staining as compared to vehicle treated cells[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 552.4±50.0 °C at 760 mmHg |
Molecular Formula | C26H24F7N3O |
Molecular Weight | 527.477 |
Flash Point | 287.9±30.1 °C |
Exact Mass | 527.180786 |
PSA | 39.60000 |
LogP | 4.79 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.545 |
Storage condition | 2-8℃ |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
RIDADR | UN 2811 6.1 / PGIII |